Dyadic Applied BioSolutions achieves milestone payments in collaborations, advances commercial focus.

• Dyadic Applied BioSolutions achieves milestone payments in collaborations with Proliant and Inzymes. • Company focuses on commercial progress and revenue growth. • Dyadic transitions to a commercially focused, revenue-driven business.

Dyadic Applied BioSolutions, a global biotechnology company, has announced significant milestone payments in its collaborations with Proliant Health & Biologicals and Inzymes ApS. These achievements highlight the company's progress in transforming its business model towards a revenue-driven approach.

In the third quarter of 2025, Dyadic reached a $500,000 milestone with Proliant for its recombinant human albumin. This milestone signifies substantial progress in the life sciences sector, with commercialization efforts underway. The company anticipates additional revenue growth as commercialization advances, with the commercial launch of recombinant human albumin targeted for late 2025 to early 2026.

Additionally, Dyadic received a $250,000 milestone payment from Inzymes for non-animal dairy enzymes. This milestone payment is a result of productivity improvements achieved in the third quarter of 2025. The first enzyme's scale-up is on track for a late 2025 launch, with additional enzyme candidates advancing as part of this partnership.

These developments underscore Dyadic's versatility and scalability in protein production across multiple markets. The company is expanding its sampling in the recombinant transferrin market and producing lab-grade DNase I, which has met performance benchmarks. Dyadic's focus on commercialization and revenue growth is evident in its recent collaborations and product advancements.

While these milestones indicate strong progress and revenue potential, Dyadic's history of net losses and reliance on third parties for production and commercialization pose ongoing financial challenges. Investors should remain cautious and closely monitor the company's future revenue generation and operational control.